Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin resistance and concurrent relative insulin deficiency and glucagon dysregulation underlie T2D pathophysiology.33–35”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alterations in these mechanisms lead to an increased fasting glucose production and impaired hepatic glucose uptake, contributing to the pathogenesis of type 2 diabetes (T2D) [1].”
From Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
The unique cytoarchitecture of human pancreatic islets has implications for islet cell function
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., & Caicedo, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510790103 · Cited by 1,312
Brüning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Hörsch, D., Accili, D., Goodyear, L. J., & Kahn, C. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80155-0 · Cited by 1,182
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals
Altarejos, J. Y., & Montminy, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3072 · Cited by 1,040
(1922) · PubMed · Cited by 753
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Research works printed but not linked: 10
- Banting, 1922, Can Med Assoc J., 12, 141
- Cherrington, 1978, Biochem Soc Symp., 43, 31
- Exton, 1970, Recent Prog Horm Res., 26, 411
- Cherrington, 1979, Am J Physiol., 236, E263
- Davis, 1985, Am J Physiol., 248, E463
- Wada, 1995, Am J Physiol., 268, E194
- Holste, 1997, Am J Physiol., 273, E488
- Baum, 1962, Diabetes., 11, 371
- Meda, 1981, C R Seances Acad Sci III., 293, 607
- Cherrinton AD. Control of glucose production in vivo by insulin and glucagon. In:Handbook of Physiology . Vol. 2. 2011:759–785. · DOI · Paper page
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
“In addition to insulin resistance, aberrant counterregu-latory hormone action in the liver also contributes to the progression of type 2 diabetes (264).”
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
“Leptin clearly has pleiotropic effects on glucose metabolism, including reduction in food intake, which reduces ectopic lipid accumulation and improves hepatic and muscle insulin action in lipodystrophic individuals (63); reduction of glucagon secretion (104); neural regulation of hepatic glucose production (105); and…”
BackgroundBiguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 833
Metabolic functions of FABPs—mechanisms and therapeutic implications
Hotamisligil, G. S., & Bernlohr, D. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.122 · Cited by 712
RNA Sequencing of Single Human Islet Cells Reveals Type 2 Diabetes Genes
Xin, Y., Kim, J., Okamoto, H., Ni, M., Wei, Y., Adler, C., Murphy, A. J., Yancopoulos, G. D., Lin, C., & Gromada, J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.018 · Cited by 692
“Hyperglucagonemia also plays a key role in the development and exacerbation of hyperglycemia in T2D (Unger and Cherrington, 2012).”
BackgroundHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Regulation of Insulin Secretion in Human Pancreatic Islets
Rorsman, P., & Braun, M. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183754 · Cited by 599
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“The pros and cons of antagonizing glucagon action for the treatment of diabetes have recently also been highlighted in several excellent review articles (184, 381, 596), and some even suggest that hyperglucagonemia rather than insulin deficiency is the key factor in the pathogenesis of diabetes (381, 596).”
BackgroundSodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ferrannini, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.011 · Cited by 340
“Secondly, due to a reduced insulin-toglucagon ratio, i.e., the prime controller of hepatic glucosemetabolism (Unger and Cherrington, 2012), fasting endogenous glucose production (EGP) is very rapidly stimulated and insulin suppression of postmeal EGP is blunted (Ferrannini et al., 2014, Merovci et…”
BackgroundVanweert, F., Schrauwen, P., & Phielix, E. (2022) · Nutrition & Diabetes · doi:10.1038/s41387-022-00213-3 · Cited by 289
“Also, antagonizing the glucagon receptors has shown to be effective in improving insulin sensitivity in models of diabetes and obesity [239].”
BackgroundMatschinsky, F. M., & Wilson, D. F. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00148 · Cited by 296
Leptin revisited: its mechanism of action and potential for treating diabetes
Coppari, R., & Bjørbæk, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3757 · Cited by 293
Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase
Owen, J. L., Zhang, Y., Bae, S.-H., Farooqi, M. S., Liang, G., Hammer, R. E., Goldstein, J. L., & Brown, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213343109 · Cited by 291
“In addition to causing a spike in plasma insulin, refeeding also causes a decline in glucagon (21).”
BackgroundIntegration of ATAC-seq and RNA-seq identifies human alpha cell and beta cell signature genes
Ackermann, A. M., Wang, Z., Schug, J., Naji, A., & Kaestner, K. H. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.01.002 · Cited by 307
“com [3,4]; however, the molecular pathophysiological mechanisms by which this occurs are not well understood.”
BackgroundBenner, C., van der Meulen, T., Cacéres, E., Tigyi, K., Donaldson, C. J., & Huising, M. O. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-620 · Cited by 302
“However, the view that hyperglucagonaemia contributes significantly to the progression of both major forms of diabetes has gained acceptance [10].”
Titchenell, P. M., Quinn, W. J., Lu, M., Chu, Q., Lu, W., Li, C., Chen, H., Monks, B. R., Chen, J., Rabinowitz, J. D., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.022 · Cited by 281
“Glucagon has been implicated in the pathogenesis of diabetes; blockade of glucagon signaling reverses the hyperglycemia of experimental diabetes (Unger and Cherrington, 2012).”
Patch-Seq Links Single-Cell Transcriptomes to Human Islet Dysfunction in Diabetes
Camunas-Soler, J., Dai, X.-Q., Hang, Y., Bautista, A., Lyon, J., Suzuki, K., Kim, S. K., Quake, S. R., & MacDonald, P. E. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.005 · Cited by 291
“Patch-seq revealed greater α-cell heterogeneity in T1D compared to ND islets, including evidence of impaired maintenance of α-cell fate, and we speculate that this might contribute to the well-recognized impairment of glucagon secretion observed in T1D (Unger and Cherrington, 2012).”
Adipocyte Lipid Chaperone aP2 Is a Secreted Adipokine Regulating Hepatic Glucose Production
Cao, H., Sekiya, M., Ertunc, M. E., Burak, M. F., Mayers, J. R., White, A., Inouye, K., Rickey, L. M., Ercal, B. C., Furuhashi, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.012 · Cited by 274
“There is an ongoing debate in the field as to whether this response is a consequence of insulin resistance or glucagon sensitivity in the liver, is secondary to an inability of insulin to suppress lipolysis effectively (Lin and Accili, 2011; Unger and Cherrington, 2012), or is due to other yet-unknown mechanisms.”
BackgroundInfluentialIslet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals
Moon, H.-S., Dalamaga, M., Kim, S.-Y., Polyzos, S. A., Hamnvik, O.-P., Magkos, F., Paruthi, J., & Mantzoros, C. S. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1053 · Cited by 258
“STAT5 deletion in the brain causes hyperphagia and obesity to a lesser extent than STAT3 deletion, suggesting that the ObRb/JAK2/ STAT5 pathway may also play a role in the regulation of body weight and energy balance by leptin (70) (Table 2).”
BackgroundAnti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones
Maianti, J. P., McFedries, A., Foda, Z. H., Kleiner, R. E., Du, X. Q., Leissring, M. A., Tang, W.-J., Charron, M. J., Seeliger, M. A., Saghatelian, A., et al. (2014) · Nature · doi:10.1038/nature13297 · Cited by 254
Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion
van der Meulen, T., Donaldson, C. J., Cáceres, E., Hunter, A. E., Cowing-Zitron, C., Pound, L. D., Adams, M. W., Zembrzycki, A., Grove, K. L., & Huising, M. O. (2015) · Nature Medicine · doi:10.1038/nm.3872 · Cited by 256
Gut-Derived Serotonin Is a Multifunctional Determinant to Fasting Adaptation
Sumara, G., Sumara, O., Kim, J. K., & Karsenty, G. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.014 · Cited by 224
“The increase in circulating serotonin levels occurred before and was not of lesser amplitude than the one of glucagon (Figure 1C), a major determinant of the adaptation to fasting (Unger and Cherrington, 2012).”
BackgroundSerotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis
Berglund, E. D., Liu, C., Sohn, J.-W., Liu, T., Kim, M. H., Lee, C. E., Vianna, C. R., Williams, K. W., Xu, Y., & Elmquist, J. K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70338 · Cited by 229
cAMP signalling in insulin and glucagon secretion
Tengholm, A., & Gylfe, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12993 · Cited by 220
“glycaemia in diabetes it has become increasingly clear that hypersecretion of glucagon contributes(120) and may even be a prerequisite for development of the disease.(48) β-Cell failure is probably the ultimate cause of glucagon hypersecretion in hyperglycaemia because of disturbed release of paracrine factors that ei…”
BackgroundInfluentialZhang, Q., Ramracheya, R., Lahmann, C., Tarasov, A., Bengtsson, M., Braha, O., Braun, M., Brereton, M., Collins, S., Galvanovskis, J., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.014 · Cited by 225
“The glucagon secretory defects include oversecretion at high glucose (when it is not needed) and inadequate release at low glucose (when it is needed) (Cryer, 2002; Unger and Cherrington, 2012).”
BackgroundAdriaenssens, A. E., Svendsen, B., Lam, B. Y. H., Yeo, G. S. H., Holst, J. J., Reimann, F., & Gribble, F. M. (2016) · Diabetologia · doi:10.1007/s00125-016-4033-1 · Cited by 223
“Nuanced interactions and crosstalk between islet cell types are critical in maintaining tight control over blood glucose equilibrium, and elucidating the ways in which enteric signals and islet cells interact to influence circulating glucose levels could provide insights into the mechanisms underlying altered glycaemi…”
BackgroundGlucagon Receptor Signaling and Glucagon Resistance
Janah, L., Kjeldsen, S., Galsgaard, K. D., Winther-Sørensen, M., Stojanovska, E., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133314 · Cited by 203
“These observations are in line with the early suggestion by Unger and colleagues that increased glucagon signaling is diabetogenic [123,124].”
ResultCalcium Signaling through CaMKII Regulates Hepatic Glucose Production in Fasting and Obesity
Ozcan, L., Wong, C. C. L., Li, G., Xu, T., Pajvani, U., Park, S. K. R., Wronska, A., Chen, B.-X., Marks, A. R., Fukamizu, A., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.002 · Cited by 215
Kazda, C. M., Ding, Y., Kelly, R. P., Garhyan, P., Shi, C., Lim, C. N., Fu, H., Watson, D. E., Lewin, A. J., Landschulz, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1643 · Cited by 212
Dean, E. D., Li, M., Prasad, N., Wisniewski, S. N., Von Deylen, A., Spaeth, J., Maddison, L., Botros, A., Sedgeman, L. R., Bozadjieva, N., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.05.011 · Cited by 211
“While traditionally thought to result from absolute or relative deficiency of insulin action, more recently the contribution of hyperglucagonemia to diabetes has been emphasized (Unger and Cherrington, 2012).”
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones
Geisler, C. E., & Renquist, B. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0513 · Cited by 191
“2011, Unger & Cherrington 2012).”
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“…been highlighted in several review articles (Unger and Cherrington, 2012; Farhy and McCall, 2015; Lee et al., 2016b; Müller et al., 2017), with the implication that excess glucagon action can serve a greater role in the pathology of T2D than impaired insulin action (Unger and Cherrington, 2012).”
BackgroundKoepsell, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.017 · Cited by 187
Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis
Holst, J. J., Wewer Albrechtsen, N. J., Pedersen, J., & Knop, F. K. (2017) · Diabetes · doi:10.2337/db16-0994 · Cited by 187
Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass
Solloway, M. J., Madjidi, A., Gu, C., Eastham-Anderson, J., Clarke, H. J., Kljavin, N., Zavala-Solorio, J., Kates, L., Friedman, B., Brauer, M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.034 · Cited by 194
Loss of β-Cell Identity Occurs in Type 2 Diabetes and Is Associated With Islet Amyloid Deposits
Spijker, H. S., Song, H., Ellenbroek, J. H., Roefs, M. M., Engelse, M. A., Bos, E., Koster, A. J., Rabelink, T. J., Hansen, B. C., Clark, A., et al. (2015) · Diabetes · doi:10.2337/db14-1752 · Cited by 172
“An increasing number of reports (26,27) has drawn attention to a-cell dysfunction in T2DM, and it is generally accepted that hyperglucagonemia plays a pivotal role in the dysregulation of glucose homeostasis (7,28).”
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
Burke, S. J., Batdorf, H. M., Burk, D. H., Noland, R. C., Eder, A. E., Boulos, M. S., Karlstad, M. D., & Collier, J. J. (2017) · Journal of Diabetes Research · doi:10.1155/2017/8503754 · Cited by 179
“Importantly, our findings are relevant to human disease because hyperglucagonemia is a key feature of the diabetic state [17, 43, 44].”
BackgroundThe Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Intraislet glucagon signaling is critical for maintaining glucose homeostasis
Zhu, L., Dattaroy, D., Pham, J., Wang, L., Barella, L. F., Cui, Y., Wilkins, K. J., Roth, B. L., Hochgeschwender, U., Matschinsky, F. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127994 · Cited by 158
Ellenbroek, J. H., van Dijck, L., Töns, H. A., Rabelink, T. J., Carlotti, F., Ballieux, B. E. P. B., & de Koning, E. J. P. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2013 · Cited by 151
Ginsenoside Rg1 Inhibits Glucagon-Induced Hepatic Gluconeogenesis through Akt-FoxO1 Interaction
Liu, Q., Zhang, F.-G., Zhang, W., Pan, A., Yang, Y., Liu, J., Li, P., Liu, B., & Qi, L. (2017) · Theranostics · doi:10.7150/thno.18788 · Cited by 158
“Although diabetes has been defined as a metabolic disorder owing to insulin deficiency or insulin resistance, accumulating evidence demonstrates that endogenous glucagon plays an essential role in the pathogenesis of diabetes, especially for hyperglycemia during fasting [2].”
Backgroundδ‐cells and β‐cells are electrically coupled and regulate α‐cell activity via somatostatin
Briant, L. J. B., Reinbothe, T. M., Spiliotis, I., Miranda, C., Rodriguez, B., & Rorsman, P. (2018) · The Journal of Physiology · doi:10.1113/jp274581 · Cited by 155
“The abnormalities in glucagon secretion in T2DM include both loss of adequate suppression under hyperglycaemic conditions and insufficient release during episodes of hypoglycaemia (Cryer, 2002, 2008; Cryer et al. 2003; Dunning et al. 2005; D’Alessio, 2011; Unger & Cherrington, 2012).”
BackgroundPAX6 maintains β cell identity by repressing genes of alternative islet cell types
Swisa, A., Avrahami, D., Eden, N., Zhang, J., Feleke, E., Dahan, T., Cohen-Tayar, Y., Stolovich-Rain, M., Kaestner, K. H., Glaser, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci88015 · Cited by 152
Metabolic manifestations of insulin deficiency do not occur without glucagon action
Lee, Y., Berglund, E. D., Wang, M.-Y., Fu, X., Yu, X., Charron, M. J., Burgess, S. C., & Unger, R. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205983109 · Cited by 151
“The fact that glucose intolerance cannot occur without glucagon receptors implies that the frequent hyperglycemic spikes might be eliminated by glucagon suppression (34, 35, 36).”
BackgroundSelf-citationThe Liver–α-Cell Axis and Type 2 Diabetes
Wewer Albrechtsen, N. J., Pedersen, J., Galsgaard, K. D., Winther-Sørensen, M., Suppli, M. P., Janah, L., Gromada, J., Vilstrup, H., Knop, F. K., & Holst, J. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00251 · Cited by 149
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
glucagon is essential for alpha cell transdifferentiation and beta cell neogenesis
Ye, L., Robertson, M. A., Hesselson, D., Stainier, D. Y. R., & Anderson, R. M. (2015) · Development · doi:10.1242/dev.117911 · Cited by 139
“Arx is a potent reprogramming factor that is essential for α cell development and maintenance (Collombat et al., 2003, 2007; Courtney et al., 2013).”
BackgroundInfluentialIntegrating the inputs that shape pancreatic islet hormone release
Noguchi, G. M., & Huising, M. O. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0148-2 · Cited by 131
Alterations in Beta Cell Identity in Type 1 and Type 2 Diabetes
Moin, A. S. M., & Butler, A. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1194-6 · Cited by 146
The Biology of Glucagon and the Consequences of Hyperglucagonemia
Wewer Albrechtsen, N. J., Kuhre, R. E., Pedersen, J., Knop, F. K., & Holst, J. J. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0090 · Cited by 129
Glucagon – Early breakthroughs and recent discoveries
Åhrén, B. (2015) · Peptides · doi:10.1016/j.peptides.2015.03.011 · Cited by 134
Molecular basis for negative regulation of the glucagon receptor
Koth, C. M., Murray, J. M., Mukund, S., Madjidi, A., Minn, A., Clarke, H. J., Wong, T., Chiang, V., Luis, E., Estevez, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206734109 · Cited by 125
“T glucagon receptor (GCGR) is a member of the class B G protein-coupled receptor (GPCR) family (1) that mediates the activity of glucagon, a pancreatic islet-derived peptide hormone that plays a central role in the pathophysiology of diabetes (2).”
BackgroundThe role of leptin in diabetes: metabolic effects
Meek, T. H., & Morton, G. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3898-3 · Cited by 132
“Several lines of evidence implicate hyperglucagonaemia in the hyperglycaemia and ketosis characteristic of uDM [25],”
BackgroundLatres, E., Finan, D. A., Greenstein, J. L., Kowalski, A., & Kieffer, T. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.007 · Cited by 117
Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans
Hansen, J. S., Clemmesen, J. O., Secher, N. H., Hoene, M., Drescher, A., Weigert, C., Pedersen, B. K., & Plomgaard, P. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.06.001 · Cited by 123
“These pathophysiological conditions often go along with insulin resistance and hyperglucagonemia [45].”
BackgroundWewer Albrechtsen, N. J., Færch, K., Jensen, T. M., Witte, D. R., Pedersen, J., Mahendran, Y., Jonsson, A. E., Galsgaard, K. D., Winther-Sørensen, M., Torekov, S. S., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4535-5 · Cited by 119
“This glucagon–amino acid feedback loop may be as important for metabolism as the glucagon–glucose loop [9].”
Hypothalamic glucagon signaling inhibits hepatic glucose production
Mighiu, P. I., Yue, J. T. Y., Filippi, B., Abraham, M. A., Chari, M., Lam, C., Yang, C. S., Christian, N. R., Charron, M. J., & Lam, T. K. T. (2013) · Nature Medicine · doi:10.1038/nm.3115 · Cited by 131
100 years of glucagon and 100 more
Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M.-M., Knop, F. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05947-y · Cited by 117
“Unger and co-workers mapped secretory responses to meal ingestion and also discovered the absolute or relative hyperglu-cagonaemia in people with type 2 diabetes [13].”
BackgroundResultInfluentialSelf-citationMidgut-Derived Activin Regulates Glucagon-like Action in the Fat Body and Glycemic Control
Song, W., Cheng, D., Hong, S., Sappe, B., Hu, Y., Wei, N., Zhu, C. C., O’Connor, M. B., Pissios, P., & Perrimon, N. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.01.002 · Cited by 124
“Glucagon, an important insulin counter-regulatory hormone, is secreted from pancreatic a cells during fasting or exercise and promotes glucose production in the liver via glucagon receptor signaling (i.e., GCGR/cAMP/PKA signaling) (Jiang and Zhang, 2003; Unger and Cherrington, 2012).”
Backgroundα-cell glucokinase suppresses glucose-regulated glucagon secretion
Basco, D., Zhang, Q., Salehi, A., Tarasov, A., Dolci, W., Herrera, P., Spiliotis, I., Berney, X., Tarussio, D., Rorsman, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03034-0 · Cited by 111
Paracrine regulation of insulin secretion
Huising, M. O. (2020) · Diabetologia · doi:10.1007/s00125-020-05213-5 · Cited by 139
Role of transcription factors in the transdifferentiation of pancreatic islet cells
van der Meulen, T., & Huising, M. O. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0290 · Cited by 125
“…in particular, is not only an avenue for the (partial) restoration of b cell mass, but it also simultaneously reduces a cell mass and thus potentially restores the balance between insulin and glucagon, which is perturbed in diabetes (Unger & Orci 2010, Unger & Cherrington 2012).”
BackgroundProtein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea
Bankir, L., Roussel, R., & Bouby, N. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00614.2014 · Cited by 111
Wang, M.-Y., Yan, H., Shi, Z., Evans, M. R., Yu, X., Lee, Y., Chen, S., Williams, A., Philippe, J., Roth, M. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424934112 · Cited by 112
“The resulting intraislet insulin concentrations are but a small fraction of the paracrine concentrations of undiluted insulin that suppress glucagon in nondiabetic subjects (8, 9).”
BackgroundSelf-citationCentral mechanisms of glucose sensing and counterregulation in defense of hypoglycemia
Stanley, S., Moheet, A., & Seaquist, E. R. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00226 · Cited by 112
The past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 109
Bernsmeier, C., Meyer-Gerspach, A. C., Blaser, L. S., Jeker, L., Steinert, R. E., Heim, M. H., & Beglinger, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087488 · Cited by 109
Glucagon secretion from pancreatic α-cells
Briant, L., Salehi, A., Vergari, E., Zhang, Q., & Rorsman, P. (2016) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2016.1156789 · Cited by 109
Kubrak, O. I., Koyama, T., Ahrentløv, N., Jensen, L., Malita, A., Naseem, M. T., Lassen, M., Nagy, S., Texada, M. J., Halberg, K. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28268-x · Cited by 105
“Paradoxical glucagon secretion under hyperglycemia is frequently observed in diabetic patients 56 .”
BackgroundSheng, L., Zhou, Y., Chen, Z., Ren, D., Cho, K. W., Jiang, L., Shen, H., Sasaki, Y., & Rui, L. (2012) · Nature Medicine · doi:10.1038/nm.2756 · Cited by 107
Kim, J. Y., Michaliszyn, S. F., Nasr, A., Lee, S., Tfayli, H. M., Hannon, T. S., Hughan, K. S., Bacha, F. F., & Arslanian, S. A. (2016) · Diabetes Care · doi:10.2337/dc16-0352 · Cited by 111
“It could be postulated that the inadequate suppression of the glucagon secretion may contribute to the monophasic response through the failure of a rapid fall in hepatic glucose production after the oral glucose load (38).”
BackgroundCamastra, S., Muscelli, E., Gastaldelli, A., Holst, J. J., Astiarraga, B., Baldi, S., Nannipieri, M., Ciociaro, D., Anselmino, M., Mari, A., et al. (2013) · Diabetes · doi:10.2337/db13-0321 · Cited by 106
“A mixed meal, however, creates a hormonal makeover by stimulating both insulin and glucagon secretion, especially in diabetic patients in whom glucagon responses are exaggerated (37).”
BackgroundParacrine control of α-cell glucagon exocytosis is compromised in human type-2 diabetes
Omar-Hmeadi, M., Lund, P.-E., Gandasi, N. R., Tengholm, A., & Barg, S. (2020) · Nature Communications · doi:10.1038/s41467-020-15717-8 · Cited by 105
Glucose and Lipid Homeostasis and Inflammation in Humans Following an Isocaloric Ketogenic Diet
Rosenbaum, M., Hall, K. D., Guo, J., Ravussin, E., Mayer, L. S., Reitman, M. L., Smith, S. R., Walsh, B. T., & Leibel, R. L. (2019) · Obesity · doi:10.1002/oby.22468 · Cited by 103
“026 HDL cholesterol (mg/dL) 44 (11) 43 (10) 46 (15) 44 (10) 0.”
BackgroundThe role of glucagon on type 2 diabetes at a glance
Godoy-Matos, A. F. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-91 · Cited by 99
“Unger RH, Cherrington AD: Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.”
BackgroundInfluentialArtemether Does Not Turn α Cells into β Cells
van der Meulen, T., Lee, S., Noordeloos, E., Donaldson, C. J., Adams, M. W., Noguchi, G. M., Mawla, A. M., & Huising, M. O. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.002 · Cited by 109
Glucose regulation of glucagon secretion
Gylfe, E., & Gilon, P. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.019 · Cited by 113
“In diabetes, lack or inappropriate secret ion of insulin is the generally accepted cause of hyperglycaemia, but Unger and Cherrington [1] recently argued that “glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes”.”
BackgroundHormonal and Metabolite Regulation of Hepatic Glucokinase
Agius, L. (2016) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071715-051145 · Cited by 101
Novel Mechanism of Foxo1 Phosphorylation in Glucagon Signaling in Control of Glucose Homeostasis
Wu, Y., Pan, Q., Yan, H., Zhang, K., Guo, X., Xu, Z., Yang, W., Qi, Y., Guo, C., Hornsby, C., et al. (2018) · Diabetes · doi:10.2337/db18-0674 · Cited by 103
“Glucagon has been implicated in the pathogenesis of diabetic hyperglycemia, largely by enhancing HGP, which is believed to be a key mechanism for pathogenesis of diabetes (36).”
BackgroundSuga, T., Kikuchi, O., Kobayashi, M., Matsui, S., Yokota‐Hashimoto, H., Wada, E., Kohno, D., Sasaki, T., Takeuchi, K., Kakizaki, S., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.10.009 · Cited by 111
“Thus, suppressing glucagon secretion could be a novel strategy for treating diabetes [4,5].”
BackgroundBriant, L. J. B., Dodd, M. S., Chibalina, M. V., Rorsman, N. J. G., Johnson, P. R. V., Carmeliet, P., Rorsman, P., & Knudsen, J. G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.035 · Cited by 98
Burak, M. F., Inouye, K. E., White, A., Lee, A., Tuncman, G., Calay, E. S., Sekiya, M., Tirosh, A., Eguchi, K., Birrane, G., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac6336 · Cited by 98
“Decreased liver glucose production and increased peripheral insulin sensitivity HGP and peripheral glucose utilization are both critical in the maintenance of normoglycemia and adaptation to feeding and fasting responses (45, 46).”
BackgroundA method for the generation of human stem cell-derived alpha cells
Peterson, Q. P., Veres, A., Chen, L., Slama, M. Q., Kenty, J. H. R., Hassoun, S., Brown, M. R., Dou, H., Duffy, C. D., Zhou, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16049-3 · Cited by 92
Ye, R., Holland, W. L., Gordillo, R., Wang, M., Wang, Q. A., Shao, M., Morley, T. S., Gupta, R. K., Stahl, A., & Scherer, P. E. (2014) · eLife · doi:10.7554/elife.03851 · Cited by 100
“…be attributed not only to the low capacity for replication and differentiation (Bouwens and Rooman, 2005) but also the detrimental cytotoxic environment that the cells are exposed to due to the dysregulation of the balance between insulin and glucagon (Robertson, 2009; Unger and Cherrington, 2012).”
BackgroundKim, T., Nason, S., Holleman, C., Pepin, M., Wilson, L., Berryhill, T. F., Wende, A. R., Steele, C., Young, M. E., Barnes, S., et al. (2018) · Diabetes · doi:10.2337/db17-1502 · Cited by 97
“Attempts to antagonize this critical metabolic pathway and thus reverse hyperglycemia have resulted in unexpected dyslipidemia, questioning whether attenuating or enhancing glucagon action is the appropriate therapeutic approach (21,22).”
BackgroundRodríguez-Rodríguez, C., Torres, N., Gutierrez-Uribe, J. A., Noriega, L. G., Torre-Villalvazo, I., Leal‐Díaz, A. M., Antunes‐Ricardo, M., Marquez-Mota, C. C., Ordáz, G., Chávez-Santoscoy, R. A., et al. (2014) · Food & Function · doi:10.1039/c4fo01092b · Cited by 101
The Roles of Vitamin A in the Regulation of Carbohydrate, Lipid, and Protein Metabolism
Chen, W., & Chen, G. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3020453 · Cited by 112
“in response to hypoglycemia, whereas insulin promotes glucose disposal, glycogenesis, and lipogenesis in response to the increase of plasma glucose levels [140].”
BackgroundLiu, L., Tian, X., Ma, Y., Duan, Y., Zhao, X., & Pan, G. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201804802 · Cited by 100
Yabe, D., Nishikino, R., Kaneko, M., Iwasaki, M., & Seino, Y. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1034105 · Cited by 103
“Such conditions might also accelerate diabetes-related sarcopenia [15], since the reduced insulin restricts uptake of glucose and amino acids into muscle and the elevated glucagon enhances proteolysis that releases amino acids for hepatic gluconeogenesis (Figure 2) [9,13].”
BackgroundSupale, S., Thorel, F., Merkwirth, C., Gjinovci, A., Herrera, P. L., Scorrano, L., Meda, P., Langer, T., & Maechler, P. (2013) · Diabetes · doi:10.2337/db13-0152 · Cited by 94
“In diabetic patients, loss of b-cells accompanied by an increase in a-cell mass has been documented and might contribute to hyperglucagonemia, precipitating hyperglycemia because of increased hepatic glucose production (38).”
Beta-Cell Dedifferentiation and Type 2 Diabetes
Dor, Y., & Gläser, B. (2013) · New England Journal of Medicine · doi:10.1056/nejmcibr1214034 · Cited by 94
Wewer Albrechtsen, N. J., Junker, A. E., Christensen, M., Hædersdal, S., Wibrand, F., Lund, A. M., Galsgaard, K. D., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00216.2017 · Cited by 98
The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes
Gilon, P. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.004 · Cited by 92
Rorsman, P., Ramracheya, R. D., Rorsman, N. J. G., & Zhang, Q. (2014) · Diabetologia · doi:10.1007/s00125-014-3279-8 · Cited by 100
“The defects in glucagon secretion include over-secretion at high glucose (when it is not needed) and inadequate release at low glucose (when it is needed) [72, 73].”
BackgroundRamracheya, R. D., McCulloch, L. J., Clark, A., Wiggins, D., Johannessen, H., Olsen, M. K., Cai, X., Zhao, C.-M., Chen, D., & Rorsman, P. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.091 · Cited by 92
“T2D is a bihormonal disorder and hyperglycemia occurs as a result of inappropriate secretion of both insulin and glucagon (Unger and Cherrington, 2012).”
Background
Metadata
- Authors
- Unger, R. H., & Cherrington, A. D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Unger, Roger H.
- ORCID
- Cherrington, Alan D.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-01-03
- Volume
- 122
- Issue
- 1
- Pages
- 4-12
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3248306
- OpenAlex
- W2113278846
- Cited by
- 670
- References
- 100
- Citations by year
- 2026: 30 · 2025: 28 · 2024: 38 · 2023: 41 · 2022: 36 · 2021: 46 · 2020: 45 · 2019: 48 · 2018: 68 · 2017: 54 · 2016: 49 · 2015: 56 · 2014: 57 · 2013: 48 · 2012: 26
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Amylin Pharmaceuticals
- University of Texas Southwestern Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, hyperglucagonemia, diabetes pathophysiology, insulin deficiency, hepatic glucose production, ketogenesis, leptin, somatostatin, glucagon receptor, pancreatic beta cells, alpha cells, anti-insulin serum
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Glucagon, Humans, Insulin, Liver, Pancreas, Glycogenolysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.